PTC Therapeutics Join Forces with Novartis to Develop PTC518 for Treating Huntington's Disease
Shots:
- PTC & Novartis have partnered to develop PTC518 Huntington's disease program, incl. related molecules, with the latter handling the development, manufacturing & commercialization post P-II (PIVOT-HD) study completion (planned in H1’25)
- PTC will receive $1B upfront, up to $1.9B development, regulatory & sales milestones plus double-digit tiered royalties on ex-US sales, with a US profit split of 40% (PTC) & 60% (Novartis). Closing is planned in Q1'25
- PTC518 is developed from PTC's splicing platform. Interim results from its P-II showed dose-dependent reductions in blood and cerebrospinal fluid (CSF) mutant Huntingtin protein and early signs of clinical benefit at 12mos., with a favorable safety & tolerability
Ref: PTC Therapeutics | Image: PTC Therapeutics
Related News:- PTC Therapeutics Reports the US FDA’s Accelerated Approval of its Gene Therapy for AADC Deficiency
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
